CELGENE CORPORATION

CELGENE CORPORATION has been granted 313 US utility patents between 2015 and 2025, placing CELGENE CORPORATION at rank #1,345 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, CELGENE CORPORATION is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 54.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 151 grants, compared with 162 in the 2015–2019 window — a -7% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. CELGENE CORPORATION's 19.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark CELGENE CORPORATION against peers pursuing similar technology classes.